McDonald's Corp vs Sanofi SA — how do they compare? McDonald's Corp trades at $273.98 (market cap $194.00B), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: McDonald's Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| MCD | SNY | |
|---|---|---|
Market Cap | $194.00B | $104.30B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $52.34 |
52-Week Low | $262.80 | $41.33 |
Enterprise Value | $247.77B | $124.19B |
Dividend Yield | 2.71% | 5.55% |
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →